fda restrictions on bpc-157 compounding Exciting news for peptides coming out of today's committee hearing! The Pharmacy Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for bpc-157 fda ban restrictions on

Prescription Weight Loss Pills Eligibility Private prescription: BMI 30+, or BMI 27+ with at least one weight-related comorbidity (PCOS, hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea) NHS (Orlistat): BMI 30+, or BMI 28+ with additional risk factors NHS (GLP-1 injections via specialist services): BMI 35+ with at least one comorbidity Where injections win - Highest efficacy - Mounjaro and Wegovy 7.2mg injection currently outperform both oral options on average weight loss Already available in the UK Weekly dosing No fasting requirements When pills make more sense - Genuine needle phobia Frequent travel where cold storage is difficult Pills draw less attention than injectable pens You take levothyroxine and orforglipron suits your existing morning routine better than the Wegovy pill Well let you decide whats better

When you are eating substantially less food than your body is accustomed to, energy levels can dip regardless of medication effects

BPC-157 occupies a separate category altogether: a tissue-targeted compound with intriguing preclinical findings but a much thinner human evidence base and a more complicated regulatory picture

Improves nervous system function and prevents disorders

This means peptides should not be viewed as replacements for proven treatments